Quick-Med Technologies, Inc. to Address Congressional 21st Century Health Care Caucus on Hospital Infection Prevention

NIMBUST Technology Showcased as a Potential Solution to Help Prevent Hospital-Acquired Infections

Washington, D.C. - June 1, 2006 - Quick-Med Technologies, Inc. (OTC Bulletin Board: QMDT) (“Quick-Med Technologies” or “QMT”)) today announced that it will present its NIMBUS™ technology as a potential solution for preventing hospital infections at a Congressional Technology Briefing to be hosted by the Unites States House of Representatives’ 21st Century Health Care Caucus. David S. Lerner, President of Quick-Med Technologies and Christopher D. Batich, Ph.D., QMT’s expert consultant and professor of Bio-Medical Engineering and Material Science at the University of Florida at Gainesville, will be present at the meeting which will be hosted by Congressmen Tim Murphy (PA-18) and Patrick J. Kennedy (RI-1), co-chairs of the Health Care Caucus. The presentation will also address health care setting applications and possible clinical trials to be conducted at Highlands Hospital, based in Connellsville, PA.

In addition to Quick-Med Technologies, other attendees will include Carolyn M. Clancy, M.D., Director of the Agency of Healthcare Research and Quality from the U.S. Department of Health and Human Services; Samuel Hammerman, M.D., Director of the Pulmonary Clinic at Highland Hospital and Medical Director at Select Specialty Hospital, Greensburg, PA; and senior representatives of Highland Hospital, including CEO Michelle P. Cunningham and Melissa Topper, R.N., Inspection Control and Education Coordinator.

The session will take place on Wednesday, June 7th, 2006 at 2:00 p.m. (EST), in the Gold Room of the Rayburn House Office Building in Washington, D.C. (By invitation only).

The NIMBUS technology employs a powerful microbicidal agent that can be permanently bonded to materials such as cotton, rayon or polyurethane to create advanced wound dressings, fabrics or other medical products. The Company has recently announced the finding that NIMBUS is highly effective against key strains of bacteria that have become resistant to antibiotics commonly used to
treat infections, including MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococcus) -- two of the most important antibiotic-resistant organisms that cause hospital and nursing home infections.(1)

In 1999, MRSA accounted for more than 50 percent of all Staphylococcus aureus infections within U.S. intensive care units (ICU). This proportion increased to more than 60 percent in 2003. VRE rates have continued to increase and now account for more than 25 percent of ICU enterococci infections, according to the National Nosocomial (hospital acquired) Infections Surveillance system. Mortality rates for VRE bacteremia and sepsis (infection in the blood) have been reported to exceed 30 percent. (2)

According to The Pennsylvania Healthcare Cost Containment Council (“PHC4”) report dated July 2005, Pennsylvania hospitals had 11,668 confirmed hospital-acquired infections in 2004. Further, according to this report, the hospital admissions in which these infections occurred were associated with 1,793 deaths, and an estimated 205,000 extra hospital days and $2 billion in additional
hospital charges. These numbers are out of a total of 1.5 million discharges from 173 general acute care hospitals.(3)

Based on current trends, it appears MRSA and VRE will be increasingly problematic, not only in acute care settings, but also in longterm care facilities and the community.

Source:

1. Quick-Med Technologies, Inc. and The University of Florida Collaborate to Develop The Next Generation of NIMBUS™ Antimicrobial Technology - September 13, 2005 Press Release
2. North Dakota Department of Health – May/June 2004 Epidemiology Report.
3. PHC4 Research Brief – Issue No. 5 July 2005: Hospital-Acquired Infections in Pennsylvania.

About Christopher D. Batich, Ph.D.
After studies in chemistry at Penn State, Rutgers and the University of Basel in Switzerland, Dr. Batich worked in the Central Research Department of DuPont for seven years. He moved to the University of Florida at Gainesville (“UF”), where he is now The Grodsky Professor of Materials Science and Engineering, and also Professor of Biomedical Engineering. He was the Founding Director of the Graduate Biomedical Engineering Program at UF, and currently serves on internal advisory boards for the Department of Surgery, the Emerging Pathogens Initiative, and also the General Clinical Research Center. He was elected as a Fellow in the American Institute of Medical and Biological Engineers (AIMBE in 1999) and has been a coauthor of about 90 peer-reviewed publications, as well as 38 patents, mostly in the area of materials for biomedical engineering.

About the House 21st Century Healthcare Caucus
The House 21st Century Health Care Caucus is a bipartisan organization of Representatives committed to realizing this transformation of the health system to deliver higher quality, safer, more efficient, and better-coordinated care.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company focused on developing broad-based technologies within the healthcare and consumer markets. The Company's two core products under development are the (1) MultiStat™ family of advanced patented methods and compounds, shown to be effective in key skin care therapy applications for cosmetic, military, and medical markets; and (2) NIMBUS™, a technology employing advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer products. Quick-Med Technologies, Inc. is listed under the symbol "QMDT" on the OTC Bulletin Board.

For additional information, visit Quick-Med Technologies' website: http://www.quickmedtech.com or email at info@quickmed-technologies.com. For Details, Contact: David S. Lerner, President at 561-750-4202. For Investor Relations, Contact: Natasha A. Sorobey at 561-208-8259

EDITOR’S NOTE: To attend briefing, please contact Niki Campbell at 412-310-6882.

© 2006 Quick-Med Technologies, Inc. All rights reserved. NIMBUS™ and MultiStat™ are trademarks of Quick-Med Technologies, Inc. All other trademarks are the property of their respective owners.

This news release may contain "forward-looking" statements, which are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, and include words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will" or similar expressions that are intended to identify forward-looking statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward- looking statements. Such statements may include, without limitation, statements concerning the Company's business model and outlook, management's ability to execute its business plan, its ability to adequately fund its operations, its ability to successfully
commercialize its technologies and/or products, its ability to protect, obtain and/or develop intellectual property rights and proprietary technology, the level of acceptance and satisfaction of its licensed products and services by end-users, and its ability to manage changing technologies and markets. Such statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, the Company's actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, including whether the Company will ever successfully launch its potential technologies and/or products, and the risk factors contained in its periodic and other filings, which are available for review at www.sec.gov. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events, or circumstances after the date of such statement.